Overview of safety of non-biologic and biologic DMARDs. - Wikidata - awgldk - TriplyDB

Overview of safety of non-biologic and biologic DMARDs.

Overview of safety of non-biologic and biologic DMARDs.

http://www.wikidata.org/entity/Q38065768

about

Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Gist and verbatim communication concerning medication risks/benefits.Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis Complicated Whipple's disease and endocarditis following tumor necrosis factor inhibitors Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population.Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.TNF inhibition for ophthalmic indications: current status and outlook.Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach.Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis.Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.Etanercept: a review of its use in autoimmune inflammatory diseases.A clinical perspective on the role of chronic inflammation in gastrointestinal cancer.Sirukumab : a novel therapy for lupus nephritis?Safety issues and concerns of new immunomodulators in rheumatology.Genetic of uveitis.A fatal case of disseminated chronic Q fever: a case report and brief review of the literature.Cutaneous side effects of TNF-alpha inhibitors.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?Medication risk communication during rheumatology office visits.Nebenwirkungen von TNF-alpha-Inhibitoren am Hautorgan.Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Refractory necrotizing scleritis successfully treated with adalimumab.Tocilizumab: A Review in Rheumatoid Arthritis.[Secondary immunodeficiency in rheumatological diseases].Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis.

P2860

Q30725001-3307FABD-48C6-403E-8F15-854B6F86277C Q33778719-0C7272F4-F9CB-4AFF-8BC3-218714B46852 Q33906679-0154432D-ED75-4162-B4B5-A08BC1E14A28 Q34411088-50FA7F08-1D9E-4A8E-B228-63CCF61DBC32 Q34780133-2CDEABD7-31ED-47AD-B87C-75156F5BD80C Q35164284-DC2FD76B-4FE8-4194-80DD-4E7E48239CA6 Q35174817-A596251B-5AA8-4007-AA13-19BBCF3399BD Q35705082-48A1E384-C4E6-4560-B7BA-0823DE941062 Q36216042-3B0F52D0-64D6-4435-8A43-D51559962DDC Q36267592-026447A2-4243-4347-B7A3-146403859BEA Q36300250-7B6E62A2-0888-4D4D-B51C-3F3268F2B7EC Q37627252-D5326441-2EF6-4266-BE79-D92C1C9E218D Q37654774-7B73DD63-FB30-455F-A258-88F2A8661592 Q37662745-D95A1DC2-D024-4C20-B081-7F53998954C0 Q38097327-C64654B7-AD42-48E0-BCB7-3687FF4E4601 Q38118781-96B6C8C0-54B5-446B-9212-B3C6AC1ED593 Q38161956-F7564D41-21DD-4D8F-86C0-5E9853EF26D9 Q38164315-3B30CC24-C7AC-4053-B798-5CA9C86D8B58 Q38182440-ADAA4F7B-BE7A-4C4B-A591-483EEF8E4140 Q38199165-CCD30CC1-1C25-454D-858E-2611E0EB22F5 Q38219589-9D80E165-4E07-41B5-BA67-F4755566B2B6 Q38230740-C65C2282-2CE0-4AC2-8197-8F5309873A24 Q38241837-ED2E1E2E-32FF-4033-83AD-41EEDBEE55D6 Q38246130-123F3BA0-A5A8-45CE-B8E1-91DD8A4EB2C1 Q38292111-58C3EDC9-DA19-433A-A5D1-B85B63FF967A Q38603345-9B17766C-C152-4F58-A245-F30A41F8A97C Q38759759-292945AD-6B20-41BB-A723-1EFF77817FC8 Q38933554-9129009F-3431-4D58-81A5-D44E9686678C Q38972531-5258812F-0729-482C-B970-BD77C90780B3 Q39042940-502A4BD6-4146-438E-84E0-25A953185DE6 Q39151827-AC7BB57E-E363-4E7C-AA2D-21EE37CED1EA Q39158058-D7C3FA44-EF4F-46B6-84D7-854D0D624CFE Q39729881-B6ADD10F-7412-4602-9FB9-E19FC8D98F6A Q40068342-3F179606-DD1A-49A0-B989-262360CCBBD9 Q40598586-87D58F6A-83CD-4996-97DB-165E9CE896AD Q41176187-E8C9C1EF-150E-4410-9719-ED9A64128353 Q42384558-7DA7ECD0-A70B-4774-98AE-6D678E2D08A9 Q43280791-899E06B4-2839-4332-9FEC-B2EA30C3E7B2 Q44975901-44C889D3-9FD6-4D1C-AF84-755F3B8CFC74 Q45903141-6D8C2ED5-38B8-41A7-A4E8-DC5135AF1846

P2860

Overview of safety of non-biologic and biologic DMARDs.

http://www.wikidata.org/entity/Q38065768

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Overview of safety of non-biologic and biologic DMARDs.

@en

type

label

Overview of safety of non-biologic and biologic DMARDs.

@en

prefLabel

Overview of safety of non-biologic and biologic DMARDs.

@en

P1433

Q38065768-9BF2DD7D-7722-489C-B0DE-93D7A7F6B006

P1476

Q38065768-971332D4-3F86-4076-85EA-ACC762635C6D

P2093

Q38065768-BD1B1645-865E-42C6-9174-A422E0C96646

P2860

Q38065768-0B19C226-731B-4519-A510-03CF300D8081

Q38065768-0FADF4FB-27CC-41BB-A921-A61BFD200CE3

Q38065768-15E7B7E1-D6F3-4E20-8E23-E4548BCBA015

Q38065768-184134C2-0496-4E2D-B1E8-AEAF3653993B

Q38065768-29955C60-526A-4309-8AF0-0346BF6A993F

Q38065768-39D9D205-250F-4107-9929-75D093D80D0B

Q38065768-3CA437A1-B542-4A44-A315-2597C244C9F4

Q38065768-3D973011-7E3C-474E-8E05-453D90428988

Q38065768-433E1F17-65A4-44D6-99F1-5436E0E13296

Q38065768-43FEB637-526F-46EC-A7B3-63DBEFDE0030

P304

Q38065768-4D077EE6-6674-4884-AECF-2F9885F5B853

P31

Q38065768-28ed5f4d-ab06-4ee1-92af-0072acd73365

Q38065768-D825C176-EBD2-4F44-9F80-A1FB44A0F633

P356

Q38065768-C4C361F7-56D0-4564-8CF1-BA541B27E04F

P478

Q38065768-95FEFFFB-46A7-4C3C-AECC-5A7F7FDEC60B

P577

Q38065768-0312C0F7-3120-4125-98B4-1423929DC856

P698

Q38065768-DBBD75CA-2A93-489D-945E-FFED95F6311A

P356

P1433

P1476

Overview of safety of non-biologic and biologic DMARDs.

@en

P2093

Eric M Ruderman

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

P304

vi37-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KES283

http://www.w3.org/2001/XMLSchema#string

P478

51 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23221586

http://www.w3.org/2001/XMLSchema#string